Cancer Profiling Market Insights 2018 to 2028| F. Hoffmann La Roche Ltd, Illumina Inc, QIAGEN, Thermo Fisher Scientific Inc, Abbott, Nanostring Technologies Inc, Siemens AG, HTG Molecular Diagnostics, Inc, Perkin Elmer Inc, Agilent Technologies Inc, Negen

Cancer Profiling Market - About the Report

Fact.MR has compiled a study on the cancer profiling and published a new report titled, “Cancer Profiling Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028.” The cancer profiling market report delivers a thorough analysis of the market that derives actionable and valuable insights.

The cancer profiling market report delivers an in-depth assessment of the market landscape that covers important dynamics such as market drivers, restraints, opportunities and trends that hold significant influence on the growth of the cancer profiling market.

The cancer profiling market report focuses on providing authentic and viable insights of the market that help readers to understand and devise strategies to enter or ensure market sustenance.

Request Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=358

Cancer Profiling Market - Competitive Landscape

In the competitive landscape of the cancer profiling market report, competition scenario of the market is explained in terms of a dashboard view of all the key players and their relative presence in the global market. The section has also identified prominent players in cancer profiling market, emerging players, mid-size players and other key players in the cancer testing market.

The section of company profiles delivers vital information such as product offerings, products in clinical trials and company developments. Few of the profiles players in the cancer profiling market report include F. Hoffmann La Roche Ltd, Illumina Inc, QIAGEN, Thermo Fisher Scientific Inc, Abbott, Nanostring Technologies Inc, Siemens AG, HTG Molecular Diagnostics, Inc, Perkin Elmer Inc, Agilent Technologies Inc, Negenomics Laboratory Inc, Genomic Health, Biogenex and Pacific Biosciences of California, Inc.

Browse Full Report @ https://www.factmr.com/report/358/cancer-profiling-market

Cancer Profiling Market Structure

The cancer profiling market is studied thoroughly for different facets such as types of cancer and associated diagnostic testing methods. In addition, regulation and reimbursement scenario is also considered to design the cancer profiling market structure. The cancer profiling market is segmented on the basis of product type, indication, end user and test type. The cancer profiling market is also studied for key regions to derive global forecast.

Based on product type, the cancer profiling market is segmented into instruments and consumables wherein instruments cover IHC, FISH, PCR instruments, DNA sequencer and fragment analyzer. The consumables segment covers reagents & kits and others ancillaries (probes, holders, etc.)

Based on indication, the cancer profiling market is segmented into breast cancer, colorectal cancer, ovarian cancer, melanoma, kidney cancer, lung cancer (including NSCLC) and rare cancer.

Hospitals, diagnostic centers, cancer research institutes and others are covered in the end-user segment of the cancer profiling market. Based on test type, the cancer profiling market is segmented into immunohistochemistry (IHC), Fluorescence in situ Hybridization (FISH), Quantitative Polymerase Chain Reaction (qPCR), Next-Generation Sequencing (NGS), Sanger sequencing and fragment analysis.

In the regional analysis, cancer epidemiology of all the key regions is thoroughly studied. Key regions included in the cancer profiling market study are North America, Latin America, Europe, CIS & Russia, Japan, APEJ and MEA.

The cancer profiling marketplace is marked by significant investments in R&D aimed at getting clinical approvals. Multiple cancer profiling tests received FDA approvals in recent past. For instance, in November 2017, FDA approved the IMPACT developed at the Memorial Sloan Kettering Cancer Center. It is an in vitro NGS-based diagnostic test with the capacity to identify a higher number of tumor biomarkers and rapid identification of mutations in 468 unique genes.

Speak To Research Analyst for Detailed Insights @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=358

Key Findings

FDA Streamlines Tedious Regulatory Process of Cancer Profiling Test Authorization

The U.S. Food and Drug Administration (FDA) regulates the safety, effectiveness, sales and distribution of cancer profiling tests. On November 15, 2017, FDA authorized Memorial Sloan Kettering Cancer Center’s (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) tumor profiling test. The test is capable of high throughput screening and identification of a higher number of mutations using biomarkers of different cancer types.

Along with this new test authorization, FDA recognized wider acceptance of cancer profiling tests for better treatment of cancer and streamlined policy framework for the efficient review process and faster availability of NGS-based cancer profiling tests. The new framework allows review of the tests by accredited third-party to reduce the test developer’s burden and streamline ensuing regulatory assessment procedures. This step has paved a way for NGS-based cancer profiling tests manufacturers to elude tedious regulatory process of authorization and faster entry to the market.

Cancer Profiling Market - Additional Questions Answered

In addition to the aforementioned insights, the cancer profiling market report delivers intelligent insights based on a thorough assessment of all the market facets. These insights can answer to some of the bemusing questions of the business professional interested in the cancer profiling market.

Which product type in the cancer profiling market will register significant demand by the end of the assessment period?
Which region presents considerable utilization of cancer profiling tools?
Among different test types, which test type will be highly sought after in the cancer profiling market during the forecast period?
Which end-user will register leading utilization of cancer profiling tests during the forecast period?
Cancer Profiling Market - Research Methodology

A robust research methodology is used to derive the insights and forecast of the cancer profiling market. Study of the cancer profiling market is based on a systematic approach that follows the methodology of the research.

The research entails elaborated interviews with industry savants as well as study of cancer profiling industry data. The former comprised primary research approach whereas the latter included secondary research. In the research methodology section of the cancer profiling market report, sources used to carry out primary and secondary research are also given that enable readers to determine the credibility of the data derived in the cancer profiling market report.

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.